免疫调节失调和潜在的向治疗在骨髓质疏松症候群
Xiaoying Zhang1, Xingcheng Yang1, Ling Ma2
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Therapeutic advances in hematology
|August 7, 2023
概括
骨髓发育综合征 (MDS) 涉及免疫系统失调,影响骨髓微环境,增加急性髓性白血病的风险. 了解这些免疫作用可能会导致新的MDS治疗方法.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 骨髓发育综合征 (MDS) 是一种克隆性造血干细胞疾病.
- MDS具有转化为急性髓性白血病 (AML) 的显著风险.
- 人们越来越了解MDS的遗传变化,但免疫系统的参与是关键焦点.
研究的目的:
- 审查免疫细胞和免疫微环境在MDS病原发生中的作用.
- 探索异常细胞因子分泌在骨髓中的影响.
- 通过了解MDS中的免疫失调来确定潜在的治疗点.
主要方法:
- 文献综述侧重于MDS的免疫学方面.
- 对MDS患者免疫细胞活性和细胞因子概况研究的分析.
- 检查骨髓微环境在疾病进展中的作用.
主要成果:
- 天生的和自适应性免疫信号在MDS的造血中被激活.
- 在MDS患者的骨髓微环境中观察到异常的细胞因子分泌.
- 免疫失调有助于破坏骨髓微环境,影响血液形成.
结论:
- 免疫失调是MDS发展和进展的关键因素.
- 了解免疫成分和MDS病原体之间的相互作用至关重要.
- 准免疫机制可能为MDS提供新的治疗策略,并防止AML转变.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Drugs for Treatment of Diarrhea-Predominant IBS
213
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
213


